SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

 by Priya Jadhav

Mumbai, January 16, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer testing and research for blood cancers and solid tumours to underserved areas in low and middle-income countries. 

Karkinos Healthcare is a purpose-driven, technology-led oncology platform, focused on early detection, advanced diagnostics, and treatment delivery of common cancers, using its Distributed Cancer Care Network across India. Karkinos Healthcare provides end-to-end solutions for the oncology ecosystem, including disease screening, diagnosis, surgery, chemotherapy, radiotherapy and comprehensive patient navigation through the care continuum, in addition to operating advanced research and development laboratories. The company is on a mission to create ‘Community as a Cancer Centre’ with an endeavour to serve one million patients annually by addressing the accessibility and affordability gaps in cancer care through a digitally curated hub and spoke and further spoke model, and not restrict cancer care to comprehensive centres alone. 

“It is our continued goal to improve health outcomes for patients globally by expanding access to precision oncology and equipping local health institutions with the tools and technology needed to practice data-driven medicine,” said Dr. Jurgi Camblong, CEO and Co-founder, SOPHiA GENETICS. “By aligning with Karkinos, who share the mutual goal, we can help increase the use of best-in-class cancer testing for rural and underserved communities around the world.” 

On this strategic partnership, Dr. R Venkataramanan, Founder and CEO, Karkinos Healthcare said, “Through collaborative research initiatives, Karkinos Healthcare aims to address the comprehensive genomic landscape identification for the Indian population, with a focus on precision medicine. This alliance will have the potential to generate evidence and world-class research for faster and accurate diagnosis and better control and management of cancers, particularly for the underprivileged population of our country.” 

The SOPHiA DDM™ Platform is designed to compute a wide array of genomic variants and continually hone machine learning algorithms to detect rare and challenging cases. Karkinos Healthcare will use SOPHiA GENETICS’ technology to expand its offerings, advance research and streamline workflow for a variety of blood cancers, including Myeloid cancer and Lymphoma. In addition, the company will analyse solid tumours for a variety of cancer types including ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers. 

The SOPHiA DDM™ Platform offers tailored NGS-based workflows to streamline processes – from sample to report – to accelerate analysis. By using the SOPHiA DDM™ Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine. 

About SOPHiA GENETICS : SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analysing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally.